Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for RP Bio Inc. (314140:KRX), powered by AI.
RP Bio Inc. is currently trading at ₩5,560. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for RP Bio Inc. on Alpha Lenz.
RP Bio Inc.'s P/E ratio is 10.3.
“RP Bio Inc. trades at a P/E of 10.3 (undervalued) with modest ROE of 4.5%.”
Ask for details →RP Bio Inc. is a biotechnology company dedicated to advancing scientific research and development in the healthcare and pharmaceutical industries. Its primary focus is on the discovery, development, and commercialization of innovative therapies aimed at addressing unmet medical needs. RP Bio Inc. engages in extensive research to develop new drug candidates, utilizing cutting-edge technologies and scientific insights. The company operates within the highly competitive biotech sector, which notably includes research institutions, pharmaceutical companies, and various healthcare organizations. RP Bio Inc. plays a vital role in the market by contributing to the pipeline of potential treatments and therapies, thereby impacting the overall landscape of medical solutions available to patients and healthcare providers. Through its commitment to innovation, RP Bio Inc. strives to make significant contributions to the lifesaving drugs and treatments that advance global healthcare.
“RP Bio Inc. trades at a P/E of 10.3 (undervalued) with modest ROE of 4.5%.”
Ask for details →RP Bio Inc. (ticker: 314140) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $48.2B.
The current price is ₩5,560 with a P/E ratio of 10.29x and P/B of 0.45x.
ROE is 4.47% and operating margin is 3.73%. Annual revenue is $136.2B.